...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
【24h】

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

机译：ESC / EAS血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.
机译：在欧洲，由动脉血管壁的动脉粥样硬化和血栓形成引起的心血管疾病（CVD）是过早死亡和伤残调整生命年（DALYs）的首要原因，在发展中国家也越来越普遍。1在欧洲联盟，CVD的经济成本每年代表直接和间接医疗保健费用E192亿1。主要临床实体是冠状动脉疾病（CAD），缺血性中风和外周动脉疾病（PAD）。这些CVD的原因是多方面的。其中一些因素与生活方式有关，例如吸烟，缺乏体育锻炼和饮食习惯，因此可以修改。其他风险因素也可以更改，例如血压升高，2型糖尿病和血脂异常，或者不可更改（例如年龄和男性）。这些指南将血脂异常的管理作为CVD预防的必要组成部分。应当始终在更广泛的CVD预防框架内考虑血脂异常的预防和治疗，这在欧洲联合会临床实践中的CVD预防工作组的指南中已解决。2-5这些指南的最新版本于20075年发布。 ;这些有关ESC /欧洲动脉粥样硬化协会（EAS）的血脂异常管理指南是对临床实践中CVD预防指南的补充，不仅针对医师[例如，对CVD预防感兴趣的全科医生（GPs）和心脏病专家，以及脂质门诊或新陈代谢部门的专家，这些专家正在处理较难分类和治疗的血脂异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号